<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Effective type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> management requires a multifactorial approach extending beyond glycaemic control </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical practice guidelines suggest targets for HbA1c, blood pressure and <z:chebi fb="23" ids="18059">lipids</z:chebi>, and emphasize weight reduction and avoiding <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The phase 3 clinical trial programme for liraglutide, a human glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 analogue, showed significant improvements in HbA1c and weight with a low risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> compared to other <z:mp ids='MP_0002055'>diabetes</z:mp> therapies </plain></SENT>
<SENT sid="3" pm="."><plain>In this context, we performed a meta-analysis of data from these trials evaluating the proportion of patients achieving a clinically relevant composite measure of <z:mp ids='MP_0002055'>diabetes</z:mp> control consisting of an HbA1c &lt;7% without <z:mp ids='MP_0005456'>weight gain</z:mp> or <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: A prespecified meta-analysis was performed on 26-week patient-level data from seven trials (N = 4625) evaluating liraglutide with commonly used therapies for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>: <z:chebi fb="0" ids="5383">glimepiride</z:chebi>, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, glargine, exenatide, <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> or placebo, adjusting for baseline HbA1c and weight, for a composite outcome of HbA1c &lt;7.0%, no <z:mp ids='MP_0005456'>weight gain</z:mp> and no hypoglycaemic events </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: At 26 weeks, 40% of the liraglutide 1.8 mg group, 32% of the liraglutide 1.2 mg group and 6-25% of comparators (6% <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, 8% <z:chebi fb="0" ids="5383">glimepiride</z:chebi>, 15% glargine, 25% exenatide, 11% <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, 8% placebo) achieved this composite outcome </plain></SENT>
<SENT sid="6" pm="."><plain>Odds ratios favoured liraglutide 1.8 mg by 2.0- to 10.5-fold over comparators </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: As assessed by the composite outcome of HbA1c &lt;7%, no <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> and no <z:mp ids='MP_0005456'>weight gain</z:mp>, liraglutide was clearly superior to the other commonly used therapies </plain></SENT>
<SENT sid="8" pm="."><plain>However, the long-term clinical impact of this observation remains to be shown </plain></SENT>
</text></document>